Lv7
4865 积分 2021-03-29 加入
FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
2天前
已完结
ADCC enhancement: A conundrum or a boon to mAb therapy?
5天前
已完结
The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy
26天前
已完结
Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment
1个月前
已完结
Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment
1个月前
已完结
T-cell engaging bispecific antibody therapy
2个月前
已完结
Fine-tuning bispecific therapeutics
2个月前
已完结
181 (PB169): DB-1419, a first-in-class bispecific ADC targeting B7-H3 and PD-L1 with a DNA topoisomerase I inhibitor, exhibits promising efficacy and safety in preclinical models
2个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
2个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
2个月前
已关闭
皖公网安备34019202002308
